BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20402561)

  • 1. Human CYPs involved in drug metabolism: structures, substrates and binding affinities.
    Lewis DF; Ito Y
    Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):661-74. PubMed ID: 20402561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity.
    Lewis DF; Ito Y
    Xenobiotica; 2009 Aug; 39(8):625-35. PubMed ID: 19514836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compound lipophilicity for substrate binding to human P450s in drug metabolism.
    Lewis DF; Jacobs MN; Dickins M
    Drug Discov Today; 2004 Jun; 9(12):530-7. PubMed ID: 15183161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling.
    Dong D; Wu B; Chow D; Hu M
    Drug Metab Rev; 2012 May; 44(2):192-208. PubMed ID: 22251142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing better drugs: predicting cytochrome P450 metabolism.
    de Groot MJ
    Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling.
    Dong D; Wu B
    Drug Metab Rev; 2012 Feb; 44(1):1-17. PubMed ID: 22242930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for CYP in the drug-hormone crosstalk of the brain.
    Meyer RP; Gehlhaus M
    Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):675-87. PubMed ID: 20201748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.
    Korolev D; Balakin KV; Nikolsky Y; Kirillov E; Ivanenkov YA; Savchuk NP; Ivashchenko AA; Nikolskaya T
    J Med Chem; 2003 Aug; 46(17):3631-43. PubMed ID: 12904067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico predictive metabolism: a structural/electronic filter method.
    Harris DL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):43-8. PubMed ID: 14982147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.
    Ekins S; de Groot MJ; Jones JP
    Drug Metab Dispos; 2001 Jul; 29(7):936-44. PubMed ID: 11408357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of density functional theory in drug metabolism studies.
    Rydberg P; Jørgensen FS; Olsen L
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):215-27. PubMed ID: 24295134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regioselectivity prediction of CYP1A2-mediated phase I metabolism.
    Jung J; Kim ND; Kim SY; Choi I; Cho KH; Oh WS; Kim DN; No KT
    J Chem Inf Model; 2008 May; 48(5):1074-80. PubMed ID: 18412330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).
    Murray M
    Int J Mol Med; 1999 Mar; 3(3):227-38. PubMed ID: 10028046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist.
    Cruciani G; Carosati E; De Boeck B; Ethirajulu K; Mackie C; Howe T; Vianello R
    J Med Chem; 2005 Nov; 48(22):6970-9. PubMed ID: 16250655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s.
    McGinnity DF; Parker AJ; Soars M; Riley RJ
    Drug Metab Dispos; 2000 Nov; 28(11):1327-34. PubMed ID: 11038161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do Fukui function maxima relate to sites of metabolism? A critical case study.
    Beck ME
    J Chem Inf Model; 2005; 45(2):273-82. PubMed ID: 15807488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.
    McGinnity DF; Griffin SJ; Moody GC; Voice M; Hanlon S; Friedberg T; Riley RJ
    Drug Metab Dispos; 1999 Sep; 27(9):1017-23. PubMed ID: 10460801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism.
    Muruganandan S; Sinal CJ
    Clin Pharmacol Ther; 2008 Jun; 83(6):818-28. PubMed ID: 18388875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.